We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc (AMLX)

( -11.23% )
Updated: 05:09:16

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
2.09 Day's Range 2.37
1.575 52 Week Range 25.48
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
US$ 3,030,229
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Pharmaceutical Preparations
Pharmaceutical Preparations
Wilmington, Delaware, USA
Amylyx Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AMLX. The last closing price for Amylyx Pharmaceuticals was US$2.36. Over the last year, Amylyx Pharmaceuticals shares have traded in a share price range of US$ 1.575 to US$ 25.48.

Amylyx Pharmaceuticals currently has 68,005,749 shares in issue. The market capitalisation of Amylyx Pharmaceuticals is US$160.49 million. Amylyx Pharmaceuticals has a price to earnings ratio (PE ratio) of 2.91.

AMLX Latest News

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for...

Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at...

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP


View all
  • Most Active
  • % Gainers
  • % Losers
CMBCambium Bio Ltd
AUD 0.40
LRLLabyrinth Resources Ltd
AUD 0.015
VPRVolt Group Ltd
AUD 0.002
TD1Tali Digital Limited
AUD 0.0015
PRXProdigy Gold NL
AUD 0.003
RHYORhythm Biosciences Limited
AUD 0.005
JTLJayex Technology Limited
AUD 0.001
EDEEden Innovations Ltd
AUD 0.001
DTIDTI Group Limited
AUD 0.009
SI6Si6 Metals Limited
AUD 0.002
ATHAlterity Therapeutics Ltd
AUD 0.007
AMDArrow Minerals Limited
AUD 0.003
FBRFBR Limited
AUD 0.05
MRQOMRG Metals Limited
AUD 0.001
LRLLabyrinth Resources Ltd
AUD 0.015

AMLX Discussion

View Posts
glenn1919 glenn1919 1 week ago
XenaLives XenaLives 2 months ago
Sounds like B.S. to me.... PHA LLC has no I.P.
Monksdream Monksdream 3 months ago
AMLX new 52 week low
XenaLives XenaLives 3 months ago
I stumbled upon this when researching taurine supplementation...

Sodium phenylbutyrate is a white or yellow powder which decomposes at about 220°C. It is freely soluble in water and
methanol; sparingly soluble in ethanol; and practically insoluble in methylene chloride, acetone, and diethyl ether.
Taurursodiol, also known as tauroursdeoxycholic acid, is an ambiphilic bile acid and is the taurine conjugate of ursodiol, also
known as ursodeoxycholic acid. The chemical name of taurursodiol is 2-[(3a, 7ß-dihydroxy-24-oxo-5ß-cholan-24-yl) amino]
ethane sulfonic acid, dihydrate. The molecular formula is C26H45NO6S . 2H2O and the molecular weight is 535.74
The taurursodiol chemical structure is:

The reason I was researching taurine is I have been taking it as a supplement for a year or more, but just discovered that I was taking a sub therapeutic dose. I altered the dosage to 3g plus and within 48 hours a tremor (most likely due to flouroquinolone poisoning) was controlled.

From Google AI:

Taurine conjugated bile acids (BAs) are cholesterol derivatives that are conjugated with taurine in the liver. Taurine is the body's most abundant free amino acid, and it plays a role in many essential functions, including development, energy production, and inflammation. BAs have antimicrobial properties that help prevent microbial colonization in the GI tract.

Versatile Triad Alliance: Bile Acid, Taurine and Microbiota - PMC
Jul 29, 2022

MTHFR Support Australia
Taurine and Its Role in Bile Synthesis
Jul 28, 2017 — Bile acids and conjugation with taurine. As bile acids are conjugated with taurine in the liver, there are several modifications that occur in hepatocytes that are vital to ensure the liver remains in a healthy state. For instance, membrane mobility, and overall fluidity of hepatocytes, increase in the presence of bile acids conjugated with taurine. Therefore, bile acids are frequently found conjugated with taurine – enabling advanced hepatocyte efficiency. Bile acid conjugation with taurine or glycine is catalyzed by two biochemical reactions: The enzyme cholyl-CoA synthetase catalyzes bile acid into acyl-CoA thioester.
Conjugation of bile acids with taurine promotes bile excretion by increasing their water solubility into bile. This facilitates the absorption of lipids and lipid-soluble vitamins. The conjugation process also makes BAs impermeable to cell membranes, allowing high concentrations to persist in bile and intestinal content.
The liver also produces taurine, and the microbiota regulates BA generation and metabolism. The rate-limiting enzymes in both taurine synthesis and BA conjugation may be regulated by a nucleus receptor, FXR, that promotes BA homeostasis.
The ratio of glycine to taurine conjugation can vary considerably. For example, in cats, BAs in the bile are exclusively conjugated with taurine. In contrast, other primates, rodents, and other Laurasiatheria exclusively conjugate bile acids with taurine but not glycine.

From the replied to post:

Relyvrio treatment a year costs 159K$ per patient.

The above text makes me wonder if this wasn't one big corporate con...

Just bumping up taurine to 3g per day has given me 80% relief from essential tremor in
We haven't been contacted by Amylyx
Scarface Scarface 3 months ago
There’s a rumor Amylyx is looking at a private company PHA LLC. They own a worldwide ALS Treatment covered by a National Institute of Health Paper and others. I found their information by doing an Internet search of, ALS/JIWULI and all the information came. It’s just a rumor but it would make sense
willlbone willlbone 3 months ago
So several employees sold shares day before bad news released. Insider trading is illegal.
scooby5 scooby5 3 months ago
Since the company is pulling the ALS drug and laying off 70% of the workforce, does the company have any other profitable drugs? How much of their revenue came from the ALS drug?
maent maent 3 months ago
They did have income from the drug in question. If they do not make them pull it, then yes, this is a no brainer.
scooby5 scooby5 4 months ago
It looks like the company has .70 in earnings and a PE in the 4’s. Were the earnings affected by the bad news on the drug trials? Seems like a no brainer to buy here if the earnings stay in the same range.
maent maent 4 months ago
Yes sir. I loaded $4 Jan25 calls.we will see how it plays out. I still haven't heard anything about them pulling the drug off the market. It does help. I'm sure we will hear something either way soon.
Monksdream Monksdream 4 months ago
AMLX under $3
maent maent 4 months ago
Seems to be settling in around the $3.15 area. Slowly loading this for a swing.
jmgreeny jmgreeny 4 months ago
All the stock give away in Jan to execs really primed the share holders to buy more.
maent maent 4 months ago
I will be very patient with this one. We await news of drug being pulled from the shelves or there is a very good chance they leave it and just change the label. If they allow it to stay on the market, this runs hard!

Nice second day cat bounce.

Looking for a higher plateau in the next few days.


maent maent 4 months ago
Nice gap that needs to be filled.
maent maent 4 months ago
Volume is ramping up steadily since noon. Nice SC-13G 4.2 Million shares.
maent maent 4 months ago
I could see this getting back to $7-10 by the end of next week.
👍️ 1
CEO_BC CEO_BC 4 months ago

Relyvrio treatment a year costs 159K$ per patient. There are 100K patient in US in need for such drug treatment. We did 110M revenue in last quarter reported at 40K$ drug costs which make it to 3K patient… from a market size of 100K (3% adoption)

The market competition for ALS is way higher than for Wolframe Syndrome.

Wolframe Syndrome has 25K patient market size in US and 25K patient in Europe. Europe has a strong need to a better drug for it. There is a strong potential that we reach quick 500M-1B$ revenue a year in the Wolframe Syndrom drugs Market.

I would assume that the company will share soon a market potential and forecast for the treatment of Wolframe Syndrome.

We were at $12 SP before we sold anything. The potential here is still way higher than $12. The larger strategic investors know this too. Expect that some will increase further holding at this price level.
CEO_BC CEO_BC 4 months ago

- pipeline below
-Book Value Per Share: 6.40
-Total Cash Per Share: 5.48
-Net Cash/Share 5.42
-Next catalyst: AMX0035 - (HELIOS)
Wolfram Syndrome: Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024.Phase 2 data due in 2H 2024.
realtmg realtmg 4 months ago
Took a position
ErnieBilco ErnieBilco 4 months ago
That's music to me ears. It was absolutely destroyed today.
maent maent 4 months ago
I flipped it a few times today. I ended up holding 2600 shares for the weekend. This is too good a company. .73 EPS is not a $3 company.
DD14 DD14 4 months ago
262 employees and 400 million in revenue in 2023, that’s why I’m taking advantage on this one drug refusal : )))) they have 5 million in cash and revenues.
DD14 DD14 4 months ago
I’m loading heavy
DD14 DD14 4 months ago
They have many other products, that’s why the market cap was 1.3 billion.
girlfriend girlfriend 4 months ago
They failed the phase3 for the Phoenix trial and are now going to huddle to see what the next steps are. That's bad news.

I didn't expect the shares to break down as much as they have but I have been a buyer today in the 2.90's up to 3.30.

Best of luck to all they have a rather clean balance sheet.

I hope you are correct, I read the the news release and did not see anything that would make investors drop this stock as much as they did.
I hope to ride this up back to $15-18 or more.


DD14 DD14 4 months ago
Watch out, next Monday this will be over $10
ErnieBilco ErnieBilco 4 months ago
Been nibbling this morning gotta be something if the price targets are maintained in the $30s
Awl416 Awl416 4 months ago
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
jmgreeny jmgreeny 5 months ago
Well their core business saved the shipped?
Scarface Scarface 5 months ago
I’ve been told, PHA signed some sort of agreement with BLUE POPPY last week. I can’t find a ticker for BLUE POPPY. I researched BLUEPOPPY.COM
They are for real. The ticker? for the reverse merger? I smell money
Scarface Scarface 5 months ago
A guy? Went on twitter last night and challenged a tweet from AMYLYX. I’m telling you this is a big problem for AMYLYX.
NASDAQ2020 NASDAQ2020 5 months ago
Have someone with Ihub subscription search for chatter on the subject

Keep an eye on Twitter too
Scarface Scarface 5 months ago

This is a fact. Read the attached article to the link above. The company behind it is PHA LLC. They own
Holders of all Trademarks Intellectual Property for JiWuLi Products in the United States and the European Union. And as of now the only compounder in the world for this treatment. Now what Amylax doesn’t want anyone to know. Ji Wu Li treatment has better results than Relyvrio. Ji Wu Li treatment costs around $1000.00 per month compared to Relyvrio at $12,000. per month. I know PHA is looking at several tickers to do a reverse merger. That ticker will make people a lot of money! Help me
Scarface Scarface 5 months ago
Amylyx is worried about a company, PHA LLC, trademark holders and intellectual property holder in the United States and the European Union for the Motor Neuron/ALS/LOU GERIG DISEASE. For the Ji Wu Li treatment, beginning in January started shipping Worldwide along with signing significant supply contracts with Neurologists around the world. I was told they were involved with the National Institute of Health published paper, Dr. Sven Schroder from Hamburg, Germany on how Ji Wu Li treatment has better results than Relyvrio at a max treatment cost of $1000.00 per month compared to $12,000.00 per month for Relyvrio. Here’s kicker, PHA are looking at several reverse merger targets. If knew the target, there’s money to be made!
👍️ 1
jmgreeny jmgreeny 6 months ago
I can’t believe nobody has been on this page for a long time

So is AMLX broken or just going thru a reboot? Any ideas or opinions or facts someone can put out there
jmgreeny jmgreeny 6 months ago
So does anybody have an opinion on this stock it’s been a while since any posying
jmgreeny jmgreeny 9 months ago
Is this company broken. Or should we just wait. Any suggestions
jmgreeny jmgreeny 10 months ago
So price of Amlx 23-24 price target 50 by financial analyst. Steady slide lower to 18.

Any news on why
conix conix 2 years ago
Another viewpoint on the ALS drug
MiamiGent MiamiGent 2 years ago
Ya Max, I see it kicking up it hoffs, want'n to go.
I have one share as a bookmark. Look'n to pounce on any dip
Have already banked nicely on this
Max77 Max77 2 years ago
Notice the cup and handle formation- super bullish chart pattern
MiamiGent MiamiGent 2 years ago
AMLX Amylyx Pharmaceuticals Receives FDA Approval Of Relyvrio For Treatment Of Amyotrophic Lateral Sclerosis
By Benzinga — 4:38 PM ET 09/29/22
MiamiGent MiamiGent 2 years ago
AMLX The Motley Fool
Sun, September 25, 2022 at 9:23 AM

AMLX Three Motley Fool contributors have joined this roundtable to scour the market for some exciting initial public offerings (IPOs) in the healthcare field. Alex Carchidi (Amylyx Pharmaceuticals): Amylyx is worth owning because there's a solid chance it'll soon commercialize the first treatment for amyotrophic lateral sclerosis (ALS) that prolongs survival time while also slowing the disease's progression. Its medicine, AMX0035, has been approved for sale in Canada since late July, and regulators at the U.S. Food and Drug Administration will weigh in on the company's application for commercialization on Sept. 29.This biotech is ready for blastoff
It's also in the final stages of preparing to launch the drug in the European Union, pending the green light from regulators, which could come in the first half of 2023.

Since its IPO in early January of this year, its shares are up by nearly 61.6%, and it'll likely rise even higher. Right now, its revenue is negligible, as there hasn't been an earnings report since the approval of its drug in Canada. But next year, analysts estimate on average that it'll bring in around $174 million if AMX0035 launches in the U.S. as planned, and that'll mean the company's top revenue growth rate should accelerate dramatically.

Amylyx Pharmaceuticals, Inc.
Today's Change
(+3.23%) $0.91
Current Price
Market Cap
Day's Range
$27.95 - $29.45
52wk Range
$6.51 - $33.41
Avg Vol
Gross Margin
Dividend Yield

Furthermore, there aren't any other ALS medicines, so Amylyx will have free rein of the global market, and that could power shareholder returns for years. And, as it already has its foot in the door thanks to its approval in Canada, it isn't as risky as other biotech stocks, though it's still not exactly a great pick for investors with a low risk tolerance.
MiamiGent MiamiGent 2 years ago

Member Level
Re: None

Friday, September 09, 2022 3:32:12 PM

622407 of 622435

AMLX I just got in at 29.80
Received recommendation of FDA Independant Advisory Committee yesterday
Up 60+% between yesterday and today.
I'm counting on "the three day rule" and publicity over weekend to send it higher Monday
A drug for ALS where there is little to offer sufferers now
sorkin sorkin 2 years ago
Bought $30 puts
sorkin sorkin 2 years ago
Sold my $30 calls

Your Recent History

Delayed Upgrade Clock